Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions: Drug: Glofitamab
Drug: Obinutuzumab
Drug: Tocilizumab
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2022-05-06

Last Posted Date: 2024-12-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT05364424

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center UCI, Orange, California, United States
🇺🇸
Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States
🇺🇸
The University of Chicago, Chicago, Illinois, United States

and more 6 locations

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1

Recruiting

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: Tarlatamab
Drug: Carboplatin
Drug: Etoposide
Drug: Atezolizumab
Drug: Durvalumab

First Posted Date: 2022-05-04

Last Posted Date: 2024-07-25

Lead Sponsor: Amgen

Target Recruit Count: 340

Registration Number: NCT05361395

Locations: 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Christiana Care Health Services, Newark, Delaware, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

and more 41 locations

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Phase 2

Recruiting

Conditions: Urothelial Carcinoma Bladder
Small Cell Neuroendocrine Carcinoma of Bladder
Bladder Cancer

Interventions: Drug: Atezolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Procedure: Cystectomy

First Posted Date: 2022-04-05

Last Posted Date: 2024-07-03

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 63

Registration Number: NCT05312671

Locations: 🇺🇸
Johns Hopkins University: Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: QL1706
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2022-04-04

Last Posted Date: 2023-05-18

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT05309629

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

Phase 3

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: pembrolizumab/vibostolimab
Biological: durvalumab
Drug: cisplatin
Drug: pemetrexed
Drug: etoposide
Drug: carboplatin
Drug: paclitaxel
Radiation: thoracic radiotherapy

First Posted Date: 2022-03-28

Last Posted Date: 2025-01-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 784

Registration Number: NCT05298423

Locations: 🇺🇸
VA Long Beach Healthcare System ( Site 2831), Long Beach, California, United States
🇺🇸
VA West Los Angeles Medical Center ( Site 2808), Los Angeles, California, United States
🇺🇸
Millennium Oncology Research Clinic ( Site 2801), Hollywood, Florida, United States

and more 157 locations

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Phase 2

Recruiting

Conditions: Multiple Myeloma
Lymphoma

Interventions: Drug: Etoposide
Drug: Cyclophosphamide
Drug: Mecapegfilgrastim, day 5
Drug: Mecapegfilgrastim, day 2

First Posted Date: 2022-03-24

Last Posted Date: 2022-12-02

Lead Sponsor: Qiu Lugui

Target Recruit Count: 120

Registration Number: NCT05294055

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 4 locations

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

Phase 1

Recruiting

Conditions: B-cell Lymphoma
Burkitt Lymphoma

Interventions: Drug: Etoposide
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Vincristine
Drug: Prednisone
Drug: Loncastuximab Tesirine 0.075 mg/kg by IV
Drug: Loncastuximab tesirine 0.12 mg/kg by IV
Drug: Loncastuximab tesirine 0.15 mg/kg by IV

First Posted Date: 2022-03-08

Last Posted Date: 2024-06-04

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 33

Registration Number: NCT05270057

Locations: 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Withdrawn

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Biological: Loncastuximab Tesirine
Drug: Melphalan

First Posted Date: 2022-02-08

Last Posted Date: 2023-01-13

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT05228249

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

Phase 3

Active, not recruiting

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Saline placebo
Biological: Pembrolizumab/Vibostolimab Co-Formulation
Drug: Etoposide
Drug: Cisplatin
Biological: Atezolizumab
Drug: Carboplatin

First Posted Date: 2022-02-04

Last Posted Date: 2024-11-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 460

Registration Number: NCT05224141

Locations: 🇯🇵
National Cancer Center Hospital East ( Site 3002), Kashiwa, Chiba, Japan
🇨🇦
Lakeridge Health ( Site 0102), Oshawa, Ontario, Canada
🇩🇪
LungenClinic Grosshansdorf-Onkologie ( Site 0903), Grosshansdorf, Schleswig-Holstein, Germany

and more 137 locations

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Pembrolizumab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2022-02-03

Last Posted Date: 2024-12-05

Lead Sponsor: University of Southampton

Target Recruit Count: 65

Registration Number: NCT05221645

Locations: 🇬🇧
Oxford Cancer & Haematology Centre, The Churchill Hospital, Headington, Oxford, United Kingdom
🇬🇧
The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy